Novo Nordisk's 4 November Referendum: Nine Countries, One Revenue Line and a Trimmed Target
Published on 11/03/2026 at 20:51 | Editorial boerse-global.de
Two separate questions are converging on Novo Nordisk's calendar, and both will be answered by the same document. The Danish drugmaker is rolling out its oral Wegovy across nine countries while simultaneously facing a skeptical reassessment of its growth trajectory — and the third-quarter report due 4 November 2026, with an earnings call to follow, sits at the intersection of both debates.
The valuation question sharpened on 26 October when SB1 Markets reaffirmed its buy rating but cut its price target to DKK 335 from DKK 370. The direction of the revision matched the mood; the investment verdict did not. That split — lower targets, unchanged conviction — is the crux for shareholders, because a reduced price objective is not by itself proof of operational deterioration, nor a measurement of its severity.
The Revenue Line That Must Carry the Expansion
What matters most in the upcoming print is the Wegovy pill's top line. Analyst consensus for the third quarter of 2026 stands at DKK 4.6 billion. That figure is the hurdle: a widening distribution map would be far less persuasive if the expansion failed to show up in revenue.
Context is unforgiving. Consensus for injectable Wegovy sits at DKK 19.9 billion, 2.1% below the prior-year quarter, and analysts expect Ozempic revenues to decline as well. The tablet therefore has to hold its own against erosion in the existing portfolio, not merely against launch expectations. A strong new product can steady the business without restoring the entire group to a durable growth path.
Geographically, the pill is now officially launched in nine countries, Germany, France and Spain among them. Following the US debut in early 2026, Mexico is slated for November 2026, while Australia — already approved — is targeted for availability by Christmas 2026. Novo attributes the phased rollout to strong demand and manufacturing capacity, which is why the pace of new country launches matters less than whether the company can actually serve demand and convert it into incremental sales while lower prices weigh on the base business.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Guidance, Not Just Growth, Sets the Bar
The second front is the outlook. Finans reported on 22 October that several banks expect a slight upgrade when nine-month 2026 results are presented. That was an analyst expectation, not a company revision — a distinction that shapes the entire setup. An improvement is already priced into sentiment, so the word "upgrade" alone will not suffice; the magnitude and the reasoning behind it must carry the weight. A merely slight raise would fulfill the described hope rather than deliver an additional positive surprise.
Jyske Bank sees room for a 2026 forecast of up to a 3% revenue decline and up to a 4% drop in operating profit, against current company guidance allowing declines of up to 6% at constant exchange rates. Even that would be a narrowing of the expected contraction, not a return to growth.
The downside scenario requires no bad news at all. Unchanged guidance could disappoint the hopes institutions have described, and a modest raise would not automatically dismantle the cautious case if the accompanying commentary permits no greater confidence.
Pipeline Promises Await Their Auditors
Scientific momentum is queued up behind the numbers, though announced presentations are not published results. Novo has 26 contributions lined up for ObesityWeek, running 14–17 November in Washington, including fresh CagriSema analyses, findings on Wegovy used as both tablet and injection, and data from the STEP-Young study. Semaglutide presentations are also scheduled at the Liver Meeting in Denver from 5 to 9 November.
One result is already on the record: a post-hoc analysis of REDEFINE 1, reported on 20 October, showed an average weight loss of 25% for women on CagriSema — a finding specific to that group and that analysis, not to all trial participants. Separately, the FDA approval of Awiqli for children aged ten and older with type 2 diabetes, announced roughly two weeks ago, is a completed regulatory step that does not by itself settle the valuation dispute dividing the analyst community.
Where the Pill Fits — and Where It Doesn't
The bull case for the tablet rests on positioning. Morningstar analyst Karen Andersen points to the head start from the early US launch and to better obesity results than Eli Lilly's Foundayo, which could help Novo build demand beyond America. A rollout free of major capacity bottlenecks would improve the sales mix and cushion declines elsewhere — provided the contribution comes from multiple markets rather than one standout country launch.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Andersen, however, sees Foundayo ahead on ease of manufacturing and speed of international rollout, so Novo's US lead is no permanent shield. Should Lilly expand its global footprint quickly, competition could cap the pill's opportunity outside the US as well. Spain illustrates a further access hurdle; an official launch there does not yet answer whether interest converts into viable demand under those conditions.
What 4 November Must Deliver
The bear case starts not with absent demand but with insufficient revenue despite rising volumes. Lower US prices pressure sales expectations while Lilly competes hard in obesity medicine, so extra prescriptions may yield less economic progress than the count of new markets suggests. Investors should also resist reading the pill's revenue in isolation: the real question is how much of the weakness elsewhere it can offset.
For now, a gradual stabilization remains plausible if pill sales meet expectations and the international build-out proceeds. Should revenues come in soft or price pressure dominate, the expansion argument for a recovery loses force. The 4 November 2026 quarterly release is the next concrete test, with attention focused on the tablet's revenue and its bearing on the full-year forecast. Mexico's planned launch will then show whether Novo is extending its international network as intended — and whether the recovery thesis amounts to demonstrably more business despite price pressure, rather than simply more reach.
Ad
Novo Nordisk Stock: New Analysis - 3 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
